⌘K
Loading ticker…
As of 2026-08-24, Ligand Pharmaceuticals Inc. (LGND) has a 3-month relative strength percentile of 83 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 63. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.6%, relative volume 0.59×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
LGND is held by 38 ETFs as of May 2026. Top owner: VTWO at 0.13% weight, $23M notional. Top 3 carry $61M.
Held by 105 ETFs · $1.0B across latest filings · largest weight 3.56% (PJP).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.13% | $23M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.10% | $22M | — |
| VIOOVanguard S&P Small-Cap 600 ETF | 0.27% | $16M | +0.02 pp |
| VHTVanguard Health Care ETF | 0.07% | $14M | +0.01 pp |
| AVSC | 0.32% | $9M |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| — |
| VIOGVanguard S&P Small-Cap 600 Growth ETF | 0.54% | $5M | +0.05 pp |
| PSCH | 2.43% | $3M | +0.11 pp |
| VTWV | 0.25% | $3M | +0.02 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $3M | — |
| GSC | 1.04% | $3M | +0.18 pp |
Showing 10 of 38 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LGND Jan avg: 4.27% median: 3.35% win: 100% σ: 3.22% n: 4 2022-04-12 → 2026-07-31 | LGND Feb avg: 5.04% median: 4.19% win: 100% σ: 2.45% n: 4 2022-04-12 → 2026-07-31 | LGND Mar avg: -4.80% median: -3.60% win: 50% σ: 7.52% n: 4 2022-04-12 → 2026-07-31 | LGND Apr avg: 1.30% median: 3.79% win: 60% σ: 10.24% n: 5 2022-04-12 → 2026-07-31 | LGND May avg: 0.67% median: -4.25% win: 40% σ: 12.29% n: 5 2022-04-12 → 2026-07-31 | LGND Jun avg: 9.96% median: 2.88% win: 80% σ: 15.45% n: 5 2022-04-12 → 2026-07-31 | LGND Jul avg: 6.41% median: 3.15% win: 60% σ: 16.18% n: 5 2022-04-12 → 2026-07-31 | LGND Aug avg: 4.66% median: -0.67% win: 50% σ: 12.24% n: 4 2022-04-12 → 2026-07-31 (current) | LGND Sep avg: -2.89% median: -6.10% win: 25% σ: 8.41% n: 4 2022-04-12 → 2026-07-31 | LGND Oct avg: 0.66% median: 3.70% win: 75% σ: 9.29% n: 4 2022-04-12 → 2026-07-31 | LGND Nov avg: 3.95% median: 8.86% win: 75% σ: 14.31% n: 4 2022-04-12 → 2026-07-31 | LGND Dec avg: -1.15% median: -7.66% win: 25% σ: 15.89% n: 4 2022-04-12 → 2026-07-31 |